| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5607942 | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
|
US5607942 (Pediatric) | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep, 2014
(9 years ago) | |
| US6716830 | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep, 2019
(4 years ago) | |
| US7671070 | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep, 2019
(4 years ago) | |
|
US7671070 (Pediatric) | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar, 2020
(4 years ago) | |
|
US6716830 (Pediatric) | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar, 2020
(4 years ago) | |
Vigamox is owned by Harrow Eye.
Vigamox contains Moxifloxacin Hydrochloride.
Vigamox has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Vigamox are:
- US5607942
- US5607942*PED
- US6716830
- US7671070
- US7671070*PED
- US6716830*PED
Vigamox was authorised for market use on 15 April, 2003.
Vigamox is available in solution/drops;ophthalmic dosage forms.
Vigamox can be used as method of combating bacteria in a patient.
The generics of Vigamox are possible to be released after 29 March, 2020.
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2003
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
VIGAMOX family patents
